A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.

A phase I trial was conducted with lobaplatin (D-19466; 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate) i.v. bolus daily for 5 days every 4 weeks. After entering five patients toxicity appeared to be related to renal function, therefore the individual dose (total dose 20-100 mg m-2 over 5 days...

Full description

Saved in:

Bibliographic Details
Main Authors:	Gietema, J. A., de Vries, E. G., Sleijfer, D. T., Willemse, P. H., Guchelaar, H. J., Uges, D. R., Aulenbacher, P., Voegeli, R., Mulder, N. H.
Format:	Artigo
Language:	Inglês
Published:	Nature Publishing Group 1993
Subjects:	Research Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC1968188/ https://ncbi.nlm.nih.gov/pubmed/8431374
Tags:	Add Tag No Tags, Be the first to tag this record!

A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.

Similar Items